Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214617 · ClinicalTrials.gov registry record · Phase 4
Effect of Crestor on Lipoprotein Metabolism in Humans
A Phase 4 study, sponsored by Foundation for Atlanta Veterans Education and Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00214617: Completed Phase 4 study, sponsored by Foundation for Atlanta Veterans Education and Research.
NCT00214617 is a Phase 4 study that has completed, run by Foundation for Atlanta Veterans Education and Research. The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214617, a Phase 4 study, has completed, sponsored by Foundation for Atlanta Veterans Education and Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.
Interventions
- DRUG Rosuvastatin at 5 mg/day and 40 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
What the finished NCT00214617 record still lists
NCT00214617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin at 5 mg/day and 40 mg/day is the first listed.
NCT00214617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00214617 about?
NCT00214617 is a clinical study titled "Effect of Crestor on Lipoprotein Metabolism in Humans". The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is exp...
What is the current status of trial NCT00214617?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2005-01. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00214617?
The interventions under investigation include: Rosuvastatin at 5 mg/day and 40 mg/day (DRUG).
Who is sponsoring clinical trial NCT00214617?
This trial is sponsored by Foundation for Atlanta Veterans Education and Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00214617's enrollment target sits among peer trials
8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia